Analysts Set MDxHealth SA (NASDAQ:MDXH) Price Target at $7.75

MDxHealth SA (NASDAQ:MDXH) has earned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.75.

A number of analysts have recently issued reports on MDXH shares. TD Cowen increased their price target on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and set a $7.00 price target on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, Lake Street Capital increased their price objective on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, November 13th.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds have recently added to or reduced their stakes in MDXH. GSA Capital Partners LLP bought a new position in MDxHealth during the third quarter valued at approximately $48,000. Lido Advisors LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter valued at $53,000. Hudson Bay Capital Management LP acquired a new stake in shares of MDxHealth in the 3rd quarter valued at $70,000. Finally, Bank of America Corp DE boosted its holdings in MDxHealth by 5,164.0% in the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares in the last quarter.

MDxHealth Stock Performance

MDxHealth stock opened at $3.56 on Tuesday. MDxHealth has a 52 week low of $1.35 and a 52 week high of $5.33. The firm has a market capitalization of $168.35 million, a price-to-earnings ratio of -5.56 and a beta of 1.62. The company has a 50 day moving average price of $3.51 and a 200 day moving average price of $3.60.

MDxHealth (NASDAQ:MDXH) last issued its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $27.43 million during the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Equities analysts forecast that MDxHealth will post -1.15 earnings per share for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.